Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 12/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.59 |
| ▸ | PGR | P06401 | 3/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.59 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | SHBG | P04278 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | AR | P10275 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL141827 | 0.92 | HIF1A (0.70) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL141359 | 0.88 | HIF1A (0.69) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL3488308 | 0.86 | HIF1A (0.70) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL141850 | 0.86 | HIF1A (0.70) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL110284 | 0.85 | NR3C2 (0.69) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL146929 | 0.84 | HIF1A (0.70) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL5488066 | 0.83 | HIF1A (0.84) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL19327149 | 0.83 | HIF1A (0.84) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL4983 | 0.83 | HIF1A (0.84) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL142560 | 0.83 | HIF1A (0.66) | HIF1ASMN1; SMN2MAPTPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019058-A1 | METHOD FOR THE TREATMENT OF VIRAL INFECTIONS | SOFTHALE NV (BE) | 2023-01-19 | — | — | US | disclosed |
| EP-4117670-A1 | METHOD FOR THE TREATMENT OF A RESPIRATORY DISEASE, DISORDER, OR CONDITION RESULTING FROM A VIRAL INFECTION | Softhale NV (BE) | 2023-01-18 | — | — | EP | disclosed |
| WO-2021180919-A1 | METHOD FOR THE TREATMENT OF A RESPIRATORY DISEASE, DISORDER, OR CONDITION RESULTING FROM A VIRAL INFECTION | SOFTHALE NV (BE) | 2021-09-16 | — | — | WO | disclosed |
| CN-109789197-A | For adjusting the composition and method of LAIR signal transduction | 奈斯科尔公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-107441480-A | Polypeptide and its purposes as the medicine for treating multiple sclerosis, rheumatoid arthritis and other autoimmune disorders | 卡姆普根有限公司 | 2017-12-08 | — | — | CN | disclosed |
| CN-103068399-A | C1ORF32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders | COMPUGEN LTD | 2013-04-24 | — | — | CN | disclosed |
| CN-1130201-C | Synergistic gold-containing compositions | MEDICAL INNOVATIONS LTD (AU) | 2003-12-10 | — | — | CN | disclosed |
| CN-1058150-C | Topical aromatic releasing compositions | RICHARD VICKS INC (US) | 2000-11-08 | — | — | CN | disclosed |
| CN-1235550-A | Synergistic gold-containing compositions | MEDICAL INNOVATIONS LTD (AU) | 1999-11-17 | — | — | CN | disclosed |
| CN-1079896-A | The compositions of topical aromatic releasing | RICHARDSON VICKS INC (US) | 1993-12-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019058-A1 | METHOD FOR THE TREATMENT OF VIRAL INFECTIONS | IL5, TSLP, CRH | HIF1A 2811/4885SMN1; SMN2 1116/4885MAPT 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.